PBE

Invesco Biotechnology & Genome ETF

$77.77

+0.00%

Market closed. Last update: 10:51 PM ET

📎 Investment Objective

The Invesco Biotechnology & Genome ETF (PBE) seeks to track the investment results of an index that is designed to provide exposure to companies engaged in the biotechnology and genome industries.

Overview

ETF tracking Invesco Biotechnology & Genome ETF

Category Technology

Issuer Invesco

Inception Date 2008-11-03

Market Cap $246.5M

Average Volume N/A

Dividend Yield 0.51%

52-Week Range $56.01 - $78.44

VWAP $77.67

Performance

Loading performance data...

Price Chart

Investment Summary

📎 Investment Objective

The Invesco Biotechnology & Genome ETF (PBE) seeks to track the investment results of an index that is designed to provide exposure to companies engaged in the biotechnology and genome industries.

🎯 Investment Strategy

The ETF employs a passive management approach, seeking to track the performance of the Dynamic Biotechnology & Genome Intellidex Index. The index is composed of U.S. biotechnology and genome companies that are selected based on a variety of investment merit criteria, such as price momentum, earnings momentum, quality, management action, and value.

✨ Key Features

Provides exposure to the biotechnology and genome sectors of the U.S. equity market
Passively tracks an index designed to identify companies with strong investment potential in these industries
Low expense ratio of 0.00%
Relatively new fund with limited performance history

⚠️ Primary Risks

Sector concentration risk, as the fund is focused on the biotechnology and genome industries
Potential for higher volatility compared to the broader market due to the specialized nature of the underlying companies
Limited performance history, making it difficult to assess long-term returns and risk characteristics
Liquidity risk, as the fund may have lower trading volume compared to more established ETFs

👤 Best For

The Invesco Biotechnology & Genome ETF may be suitable for investors seeking exposure to the biotechnology and genome sectors as part of a diversified portfolio. It may be of particular interest to investors with a higher risk tolerance and a long-term investment horizon, as the biotechnology and genome industries can be subject to significant volatility.